An observational study in Centronuclear Myopathy, sponsored by University of Erlangen-Nürnberg Medical School. Recruiting at 1 site in Germany. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-15.
Sponsored by University of Erlangen-Nürnberg Medical School · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Twenty patients with centronuclear myopathy and twenty age- and sex-matched, muscle-healthy controls will undergo diagnostic examination. Study participants will undergo physical examination, clinical and functional testing, and multispectral optoacoustic tomography (MSOT) scanning at predefined muscle sites (paraspinal muscles, trapezius muscle, deltoid muscle, forearm flexors, quadriceps muscle, adductor muscles, ischiocrural muscles, triceps surae muscle, and tibialis anterior).
Centronuclear myopathy (CNM) belongs to the group of congenital myopathies. These are named after their histopathological feature: the nucleus is localized in the center of the muscle cell instead of its physiological position at the periphery. CNM is so rare that there are only epidemiological data available for the group of congenital myopathies as a whole. The incidence is estimated at 0.06 per 1,000 live births.
CNM is genetically and clinically heterogeneous. Identified gene mutations affect proteins involved in membrane remodeling, transport, and excitation-contraction coupling.
Patients with CNM usually present with muscle weakness and hypotonia in early childhood. The severity of the disease varies depending on the underlying genotype and ranges from reduced exercise tolerance and ptosis to floppy infant syndrome and respiratory failure. One example of a very severe course is the X-linked form caused by a Myotubularin 1 (MTM1) nonsense mutation (XL-MTM). Affected patients become symptomatic in the neonatal period and usually die in childhood or adolescence. In contrast, patients with the Dynamin 2 (DNM2) mutation have a later onset and milder disease progression. In the few reported patients with Bridging Integrator 1 (BIN1) mutations, onset occurs in infancy or adulthood with a moderate disease course. Ryanodine receptor 1 (RYR1)-associated CNMs also vary in terms of age of onset and disease severity.
Diagnosis is based on molecular genetic testing and muscle biopsy. However, these techniques are not widely available, are time-consuming, and invasive. Anesthesia is usually required for young patients.
Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin, or hemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT uses near-infrared light pulses that are absorbed by tissue, causing thermoelastic expansion of certain molecules. This expansion generates ultrasound waves, which are then detected by the same device. The multispectral illumination and signal unmixing enable precise localization and quantification of muscle-specific subcellular structures. MSOT has already demonstrated the potential to visualize muscle structure and disease extent in patients with Duchenne muscular dystrophy, spinal muscular atrophy, and late-onset Pompe disease (LOPD), and to distinguish these patients from healthy volunteers. To date, there are no optoacoustic data available for CNM.
The aim of this study is to gain molecular insights into muscle degeneration in CNM patients for the first time. To develop a comprehensive picture of the optoacoustic characteristics of CNM, patients of different ages and disease severities will be recruited. Due to the rarity and small number of CNM cases, recruitment is challenging. Therefore, the opportunity should be taken to offer study participation to as many patients as possible at the patient meeting in Bad Nauheim from May 29 to June 1, 2025. In addition to non-invasive, radiation-free imaging, clinical-functional tests will be conducted as part of the study. These include muscle strength testing (MRC score) and the timed "get up and go" test. Various accessible muscle groups will be scanned using MSOT, including the paraspinal muscles and trapezius muscle, as well as the following limb muscles on both sides: deltoid, biceps brachii, forearm flexors, quadriceps femoris, adductors, hamstrings (ischiocrural muscles), triceps surae, and tibialis anterior.
24 studies on the registry are indexed under Myopathies, Structural, Congenital; 10 are open to participants now.
This study's planned enrollment of 40 is below the median of 49 across 12 observational studies indexed under Myopathies, Structural, Congenital.
Browse Myopathies, Structural, Congenital studies →University of Erlangen-Nürnberg Medical School is the lead sponsor of 277 studies on the registry; 53 are open to participants now.
Counted across the registry records on this site, refreshed daily.
n= 20 CNM n = 20 HV
CNM arm:
Inclusion Criteria: diagnosed CNM; minimum of 2 years of age
Exclusion Criteria:
HV:
Inclusion criteria: minimum of 2 years of age
Exclusion criteria:
patients with diagnosed centronuclear myopathy
Diagnostic Test: MSOT
Healthy control
Diagnostic Test: MSOT
Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin or haemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT illuminates the tissue with near-infrared light of transient energy, which is absorbed and leads to thermoelastic expansion of certain molecules. This expansion generates ultrasound waves that are detected by the same device. The multispectral illumination and unmixing then enable the precise localization and quantification of muscle-specific subcellular structures. MSOT has already shown the potential to visualize the muscle structure and clinical extent of muscle disease in patients with Duchenne muscular dystrophy, spinal muscular atrophy and the late-onset Pompe disease (LOPD) and to distinguish these patients from healthy volunteers. To date, there is no optoacoustic data on CNM.
Optoacoustic spectrum of MSOT Imaging (all in arbitrary units)
Comparison of optoacoustic spectrum from patients with diagnosed CNM and their age- and sex matched Healthy Volunteers
Time frame: Day 1
Comparison of MSOT-Derived Hemoglobin and Myoglobin Signals
Quantitative comparison of MSOT-derived hemoglobin and myoglobin signals (arbitrary units).
Time frame: Day 1
Comparison of Oxygenated vs. Deoxygenated Hemoglobin Signal
Quantitative comparison of oxygenated and deoxygenated hemoglobin signals.
Time frame: Day 1
Comparison of Oxygenated Hemoglobin and Lipid Signal
Quantitative comparison of oxygenated hemoglobin and lipid signals.
Time frame: Day 1
Comparison of deoxygenated Hemoglobin and Lipid Signal
Quantitative comparison of deoxygenated hemoglobin and lipid signals.
Time frame: Day 1
Comparison of oxygenated Hemoglobin and Collagen Signal
Quantitative comparison of oxygenated hemoglobin and collagen signals.
Time frame: Day 1
Comparison of deoxygenated Hemoglobin and Collagen Signal
Quantitative comparison of deoxygenated hemoglobin and collagen signals.
Time frame: Day 1
Comparison of Lipid and Collagen Signal
Quantitative comparison of Lipid and collagen signals.
Time frame: Day 1
Comparison of Lipid and Myoglobin Signal
Quantitative comparison of Lipid and Myoglobin signals.
Time frame: Day 1
Comparison of Collagen and Myoglobin Signal
Quantitative comparison of Collagen and Myoglobin signals.
Time frame: Day 1
Correlation of Hemoglobin Signal with Disease Duration and Patient Age
Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)
Time frame: Day 1
Correlation of Myoglobin Signal with Disease Duration and Patient Age
Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)
Time frame: Day 1
Correlation of oxygenated and deoxygenated Hemoglobin Signal with Disease Duration and Patient Age
Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)
Time frame: Day 1
Correlation of Lipid Signal with Disease Duration and Patient Age
Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)
Time frame: Day 1
Correlation of Collagen Signal with Disease Duration and Patient Age
Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)
Time frame: Day 1
Correlation of Hemoglobin Signal with MRC Muscle Strength
Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Time frame: Day 1
Correlation of Myoglobin Signal with MRC Muscle Strength
Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Time frame: Day 1
Correlation of oxygenated and dexoygenated Hemoglobin with MRC Muscle Strength
Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Time frame: Day 1
Correlation of Lipid Signal with MRC Muscle Strength
Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Time frame: Day 1
Correlation of Collagen Signal with MRC Muscle Strength
Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Time frame: Day 1
PDFs hosted by the registry, ClinicalTrials.gov.
Started May 2025 (actual). Primary completion is estimated for Oct 2025, 5 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myopathies, Structural, Congenital →
University of Erlangen-Nürnberg Medical School →